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Abstract
Although the etiology of schizophrenia remains unknown, diverse neuropathological evidence
suggests a disorder of synaptic connectivity. Apoptosis is a form of cell death that helps determine
synaptic circuitry during neurodevelopment and altered regulation of apoptosis has been
implicated in schizophrenia. Prostate apoptosis response-4 (Par-4) is an upstream regulator of
apoptosis preferentially localized to synapses. Brain Par-4 levels are upregulated in response to
pro-apoptotic stimuli in rodent models and in patients with classic neurodegenerative diseases.
Recently, Par-4 was also found to form a complex with the dopamine D2 receptor (D2DR) in
competition with the calcium-binding protein calmodulin, implicating Par-4 as an important
regulatory component in normal dopamine signaling. Interestingly, mutant mice with disrupted
Par-4/D2DR interaction demonstrated depressive-like behaviors, suggesting a potential role for
Par-4 in both depression and schizophrenia. In this study, Par-4, D2DR and calmodulin protein
levels were measured using semiquantitative Western blotting in postmortem temporal cortex in
subjects with schizophrenia, major depression and bipolar disorder. Compared to normal controls,
mean Par-4 levels appeared slightly lower in schizophrenia and bipolar disorder. However, in
major depression, Par-4 was decreased by 67% compared to normal controls. No differences were
found between any groups for calmodulin or for the D2DR 48 kDa band. The D2DR 98 kDa band
was lower by 50% in the schizophrenia compared to control groups. Changes in the Par-4/D2DR
signaling pathway represent a novel mechanism that may link apoptotic and dopamine signaling
pathways in major depression and schizophrenia.
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A number of consistent neuropathological findings in the cortex of subjects with
schizophrenia have emerged. These include smaller neurons (Rajkowska et al., 1998; Pierri
et al., 2001), reduced gray matter volume (Wright et al., 2000), decreased neuropil (Selemon
and Goldman-Rakic, 1999) and an absence of gliosis (Benes et al., 1991). Furthermore,
longitudinal neuroimaging studies indicate that some gray matter loss is progressive,
especially early in the course of the illness (DeLisi et al., 1997; Cahn et al., 2002). While
large scale reductions in cortical neuronal populations have not been found (Akbarian et al.,
1995; Rajkowska et al., 1998), regional and layer-specific reductions have been reported
(Benes et al., 1991; Benes et al., 2001), as well as reductions in glial populations (Cotter et
al., 2001; Stark et al., 2004). In addition, findings of decreased synaptic markers (Eastwood
and Harrison, 1995; Glantz and Lewis, 1997) and decreased dendritic length and spine
density (Garey et al., 1998; Glantz and Lewis, 2000) suggest that cortical synaptic circuitry
is altered. While the pathophysiological basis of these deficits remains unknown, a role for
apoptosis in schizophrenia has previously been proposed (reviewed by Glantz et al., 2006).
Apoptosis is a form of cell death that is pervasive during prenatal development of the human
central nervous system (CNS), serving to eliminate excess neurons so as to refine synaptic
connectivity within and between brain regions. Apoptotic mechanisms can also exert direct
effects on local synaptic elimination in a process sometimes called synaptic apoptosis
(Glantz et al., 2006). The rate of neuronal apoptosis in the CNS slows dramatically during
later development, but can be activated in order to eliminate injured or diseased neurons.
Prostate apoptosis response-4 (Par-4) is a pro-apoptotic protein first identified in prostate
cancer cells undergoing apoptosis (Sells et al., 1994). Par-4 is expressed in neurons – but not
glia – with preferential localization to synapses in most cortical regions (Boghaert et al.,
1997; Guo et al., 1998; Guo et al., 2001). Levels of Par-4 are increased in multiple brain and
spinal cord regions in patients with classic neurodegenerative illnesses such as Alzheimer's
disease (Guo et al., 1998) and amyotrophic lateral sclerosis (Pedersen et al., 2000). Neuronal
levels of Par-4 are rapidly increased following exposure to pro-apoptotic stimuli such as
neurotrophic factor deprivation and hypoxia/ischemia (Guo et al., 1998; Duan et al., 1999).
Par-4 upregulation is also known to suppress expression of the neuroprotective anti-
apoptotic Bcl-2 protein in transgenic cells (Camandola and Mattson, 2000), potentially
contributing to reduced Bcl-2 levels found in postmortem temporal cortex in schizophrenia
(Jarskog et al., 2004; Jarskog et al., 2000). During apoptosis, Par-4 is thought to regulate
mitochondrial function and caspase cleavage via its leucine zipper domain (Guo et al., 1998;
Chan et al., 1999; Duan et al., 1999). Interestingly, a recent study found that Par-4, together
with calmodulin, also exerts a physiological role in dopamine D2 receptor (D2DR) signaling
(Park et al., 2005).
Given these converging lines of data, Par-4, calmodulin and D2DR were measured in
postmortem temporal cortex of subjects with schizophrenia, major depression, bipolar
disorder and in normal controls. It was hypothesized that evidence for altered cortical Par-4
levels could represent a mechanism relating apoptotic dysregulation to deficits in dopamine
signaling in schizophrenia.
2. Materials and Methods
2.1 Subjects
Frozen temporal cortical specimens from 60 human brains were obtained from the Stanley
Foundation Neuropathology Consortium (Bethesda, Maryland). Brain tissue was collected
as described in detail by Torrey et al. (2000). In brief, the Stanley Foundation received
specimens from four state medical examiners that were collected using standardized
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protocols for tissue procurement and processing. DSM-IV diagnoses were determined by
two senior psychiatrists using all available medical records and from family interviews.
Subjects over 68 years of age were excluded from the collection to reduce the likelihood of
comorbid neurological disorders.
Samples were group-matched for age, gender, ethnicity, brain hemisphere, brain pH, and
postmortem interval (PMI) and consisted of four diagnoses: normal control, schizophrenia,
bipolar disorder, and major depressive disorder (Torrey et al., 2000), see Table 1 and online
supplementary information for additional demographic and biochemical data for each
postmortem subject. Groups consisted of 15 subjects each except for the following
experiments where certain groups were decreased in number due to limited tissue
availability: synaptophysin (schizophrenia = 14; bipolar disorder = 14); D2DR (normal
control = 14; schizophrenia = 14; bipolar disorder = 14); and calmodulin (normal control =
14; schizophrenia = 13; bipolar disorder = 13). All samples were stored at -80°C until use.
All procedures were approved by the Institutional Review Board of the University of North
Carolina School of Medicine.
2.2 Western Blot Procedures
Tissue blocks (100-300 mg) from temporal cortex (Brodmann area 21) were placed in 10
volumes of 10 mM HEPES buffer (pH 7.0) with 0.32 M sucrose, 0.1 mM
phenylmethylsulfonyl fluoride (PMSF), 10 μg/ml aprotinin, 5 μg/ml pepstatin A, 1 mM
benzamidine, 0.1 mM benzethenium chloride. Samples were homogenized (PowerGen 125,
Fisher Scientific) on ice for 30 sec and sonicated (Sonic Dismembrator 60, Fisher Scientific)
for 10 sec at 10 mV. Samples were centrifuged for 15 min at 15,000 x g at 4°C. Supernatants
were assayed for total protein by the BCA method (Pierce, Rockford IL). All chemicals
were obtained from Sigma-Aldrich (St. Louis, MO).
Western blotting experiments were performed to measure the relative levels of Par-4, D2DR
and calmodulin. Synaptophysin was also measured to control for total synaptic content. For
each protein, three separate Western blot experiments were run for all 60 samples. Samples
were separated on 10% (synaptophysin and Par-4), 4-12% (D2DR) or 10-20% (calmodulin)
Tris-glycine polyacrylamide gels using a mini-cell electrophoresis unit (Invitrogen, Carlsbad
CA). Equal amounts of protein (Par-4, D2DR: 100 μg; synaptophysin: 1 μg; calmodulin: 10
μg) were boiled for 5 min and loaded into wells. All gels were run with a low-range
molecular weight marker (Rainbow MW Marker, Amersham Pharmacia, Piscataway NJ or
Magic Mark XP, Invitrogen, Carlsbad CA). Par-4-stained gels were run with Par-4 protein
(Santa Cruz Biotechnology, Santa Cruz CA) controls and D2DR-stained gels were run with
SK-N-SH cell lysate (Santa Cruz Biotechnology). Separated proteins were transferred to
polyvinylidene difluoride (PVDF) membranes (Immobilon-P, Millipore MA) at 25V for 90
min and complete and uniform transfer was verified by staining membranes with Ponceau S.
Non-specific protein binding was blocked with 5% milk in 0.1% Tween TBS. Membranes
were incubated overnight at 4°C with primary antibodies as follows: rabbit polyclonal Par-4
(1:1000; Santa Cruz Biotechnology), mouse monoclonal synaptophysin (1:2000; Sigma-
Aldrich), goat polyclonal D2DR (1:100; Santa Cruz Biotechnology) and rabbit polyclonal
calmodulin (1:8000; Abcam Inc., Cambridge MA) in 5% milk. Membranes were then
washed and incubated for 1 hr with a HRP-conjugated secondary antibody in 5% milk
(Par-4: 1:2000, Synaptophysin: 1:4000, calmodulin: 1:3000, Amersham Pharmacia; D2DR:
1:3000, Sigma-Aldrich). Membranes were washed and then immunoreactivity was
visualized using chemiluminescence (ECL, Amersham Pharmacia) and proteins bands were
detected on radiographic film (Hyperfilm ECL, Amersham Pharmacia). Optical
densitometry measurements were performed in a blinded manner and integrated optical
density (OD) was determined using a computerized image analysis system (Bioquant,
Nashville TN). Raw ODs were normalized to a pooled control sample consisting of equal
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protein amounts of each brain sample which was applied to each blot to allow for intergel
comparisons. Membranes were also stripped using IgG Elution Buffer (Fisher Scientific)
and reprobed with a polyclonal rabbit antibody to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (1:60,000, Imgenex, San Diego CA) in order to confirm equal
loading across samples. GAPDH levels were unchanged across diagnostic groups by
ANOVA (F3,55=0.67, P=0.58). In addition, a standard curve of the pooled control sample
was immunoblotted to ascertain that tissue samples fell within the linear portion of the
densitometric curve (data not shown).
2.3 Par-4 Immunohistochemistry
To provide a qualitative assessment of the cellular and subcellular distribution of Par-4 in
human cortex, sections from control subjects were processed for Par-4
immunohistochemistry. Tissue sections from the same temporal cortical area used for the
Western blot experiments were not available. However, frozen sections (14 μm thick) from
prefrontal cortex from the same control group subjects were available for this study.
Sections were pretreated in aqueous 1% hydrogen peroxide for 30 min at room temperature
in order to remove endogenous peroxidase activity, washed, and then incubated at room
temperature for 30 min in phosphate-buffered saline (PBS) containing 0.3% Triton X-100
and 4.5% normal goat serum. Sections were incubated overnight at 4°C in PBS containing
0.3% Triton X-100, 0.05% bovine serum albumin, 3% normal goat serum and a polyclonal
antibody that specifically recognizes Par-4 (1:1000; Santa Cruz Biotechnology, Santa Cruz
CA; Boghaert et al. 1997). Sections were then processed using a standard Vectastain ABC
kit (Vector Laboratories, Burlingame CA) and diaminobenzidine.
2.4 Rat Models of Postmortem Stability and Antidepressant Treatment Effects
In order to determine the effects of postmortem interval on the proteins analyzed in this
study, male Sprague-Dawley rats (150-200 g, Charles River, Raleigh NC) were killed and,
in one group (n=6), frontal cortex was dissected and immediately frozen at -80°C. To
approximate the human postmortem condition, heads of the other group (n=7) were kept at
25°C for 6 h and then at 4°C for 18 h, after which the frontal cortex was dissected out and
frozen.
To determine whether antidepressant medication influenced protein levels, cortical tissue
homogenates were obtained from Flinders Sensitive Line (FSL) rats, a preclinical model of
depression (Overstreet et al., 2005), and Flinders Resistant Line (FRL) rats (n=8 per group).
FRL rats served as a control group for the FSL condition. FSL rats received daily
intraperitoneal injections for 14 days with vehicle or desmethylimipramine (5 mg/kg) while
FRL rats received vehicle only.
All rat tissues were homogenized and sonicated, and Western blots of Par-4, D2DR and
calmodulin were performed as described in section 2.2 with the following exceptions for the
Par-4 Westerns: 25 ug total protein per sample was loaded onto 4-12% Tris-glycine gels and
the primary Par-4 antibody dilution was 1:2000.
2.5 Statistical Analysis
Western blot data from human and rat tissue were analyzed by one-way analysis of variance
(ANOVA) with significance set at α=0.05. Post hoc analyses using the Tukey's multiple
comparison test were performed using two-tailed P values considered significant at α= 0.05.
Statistical analysis was performed using GraphPad Prism (Version 4.01 GraphPad Software,
San Diego CA).
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3.1 Par-4 Western Blot
Par-4-immunoreactive bands were visualized in each cortical sample, demonstrating a
migration pattern similar to previous Western blot studies (Park et al., 2005). Antibody
specificity was confirmed using a Par-4 positive control fusion protein (Figure 1). Par-4
levels demonstrated a significant effect of diagnosis by ANOVA (F3,56=2.9, P<0.05; Figure
2). Although mean Par-4 band immunoreactivity in subjects with schizophrenia and bipolar
disorder were 46% and 31% lower than controls, respectively, these differences were not
significant using post hoc Tukey's multiple comparison tests. However, mean Par-4 band
immunoreactivity was 67% lower in subjects with major depression compared to normal
control subjects (P<0.05). Par-4 values did not correlate with PMI or pH.
3.2 D2DR Western Blot
Two prominent bands were identified for D2DR at 48 and 98 kDa (Figure 3). The 48 kDa
band represents the receptor monomer and the 98 kDa band is the receptor dimer, consistent
with prior Western blot studies of D2DR in human brain (Zawarynski et al., 1998). For the
48 kDa band, no differences were seen between the subject groups by ANOVA
(F3,53=0.998, P=0.4; Figure 4A). However, for the 98 kDa band, a significant effect of
diagnosis was seen by ANOVA (F3,53=3.3, P<0.05; Figure 4B). A post hoc Tukey's multiple
comparison test found that mean D2DR 98 kDa band level was lower by 55% (P<0.05) in
subjects with schizophrenia compared to normal control subjects. Numerically, 98 kDa
levels were also lower for bipolar disorder (50%) and major depression (53%) compared to
normal controls but these differences did not reach statistical significance. Par-4 values and
the 98 kDa band showed a positive linear correlation across all samples (F1,55=12.2, P<0.05,
r2=0.18). The 98 kDa levels did not correlate with PMI or pH.
3.3 Calmodulin Western Blot
Calmodulin-immunoreactive bands were seen at the expected molecular weight of 17 kDa in
each of the samples. Mean calmodulin levels did not differ across diagnostic groups by
ANOVA (F3,51=0.48, P=0.70; Figure 5). Par-4 and calmodulin levels did not correlate
(F1,53=1.6, P=0.21, r2=0.03).
3.4 Synaptophysin Western Blot
Synaptophysin-immunoreactive bands were seen at the predicted molecular weight of 38
kDa (data not shown). Mean synaptophysin levels did not differ across diagnostic groups by
ANOVA (F3,54=1.92, P=0.14; Figure 6). Numerically, mean synaptophysin levels in
subjects with schizophrenia, bipolar disorder and major depression were 41%, 45% and 1%
lower compared to normal control subjects but these differences were not statistically
significant. These findings suggest that the decrease in Par-4 levels in subjects with major
depression compared to normal controls is not secondary to reduced synapses in this region.
3.5 Par-4 Immunohistochemistry
Immunohistochemistry of frozen prefrontal cortical sections demonstrated a subset of Par-4
immunoreactive neurons in normal control subjects (see Figure 7). Some of these neurons
exhibited a pyramidal shape. Par-4 immunoreactivity could be seen in the cell body,
extending into the proximal pyramidal and basilar dendrites. Other immunoreactive neurons
were smaller and round, presumably representing nonpyramidal neurons since in vitro and
animal studies indicate that Par-4 is not expressed in glia. In addition, immunoreactivity
within the cortical neuropil exhibited a punctate pattern, consistent with synaptic
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localization of Par-4 protein. The distribution of Par-4 in human cortex is not known to have
been demonstrated previously.
3.6 Protein Postmortem Stability
In order to determine whether PMI affected Par-4 and D2DR levels, rodent brains were
subjected to a PMI of 0 or 24 hours. Using this model, Par-4 levels were decreased by 54%
after 24 hours PMI (t=0.006, P<0.05). Neither the 48 kDa band (t=0.85, P>0.05) nor the 98
kDa band (t=0.08, P>0.05) of the D2DR showed significant effects of PMI.
3.7 Effects of Antidepressant Medication on Protein Levels
Because Par-4 levels were decreased in subjects with major depression, we examined the
potential effects of antidepressant medication on Par-4 in two ways. First, Par-4 levels were
compared between those subjects with major depression who were (n=10) and were not
(n=5) receiving antidepressants at the time of death. No differences were found between
these two groups (t=0.07, P>0.05). Second, Par-4 was measured in the FSL rat model of
depression (Overstreet et al., 2005) as follows: FSL antidepressant-treated, FSL vehicle-
treated and FRL control rats. No differences in Par-4 levels were found among these 3
groups (Figure 8). D2DR and calmodulin levels were also examined in these three groups
and no differences were seen (data not shown). These represent several lines of evidence
that antidepressant treatment did not confound the human postmortem data.
4. Discussion
The known functions of Par-4 include well-established pro-apoptotic effects (Guo et al.,
1998) as well as more recently discovered involvement in D2DR signaling (Park et al.,
2005). In this study, we sought to determine whether Par-4 protein was altered in temporal
cortex of subjects with schizophrenia, major depression and bipolar disorder. Although
Par-4 levels appeared somewhat lower in subjects with schizophrenia and bipolar disorder
compared to normal controls, these differences did not reach statistical significance.
However, mean Par-4 levels were decreased by 67% in major depression compared to
controls. Interestingly, this supports a Par-4 mutant mouse model of depression in which
Par-4 binding to D2DR is disrupted, effectively reducing Par-4 availability for normal
D2DR signaling (Park et al., 2005). Par-4 mutant mouse behavioral phenotype included
increased immobility during the forced swim test, increased latency to contact novel food,
and decreased open-field exploration. The substantial reduction of Par-4 abundance in
postmortem cortex in major depression may functionally replicate altered Par-4/D2DR
signaling seen in the Par-4 mouse model and suggests pathophysiological relevance of low
cortical Par-4 levels.
Cortical levels of the D2DR 98 kDa dimer were approximately 50% lower in schizophrenia,
major depression and bipolar disorder compared to normal controls, although only the
schizophrenia group reached statistical significance. A role for dopamine dysregulation has
long been demonstrated in schizophrenia (reviewed by Guillin et al., 2007), including
several lines of evidence for altered D2DR signaling in temporal cortex, such as PET studies
of D2/3 receptors showing decreased binding in the temporal cortex of drug-naïve subjects
(Tuppurainen et al., 2003; Buchsbaum et al., 2006) altered distribution of D2DR in
postmortem temporal lobe (Goldsmith et al., 1997) and reduced Akt1 levels, an anti-
apoptotic protein downstream from D2DR that helps regulate dopamine neurotransmission
in frontal cortex and hippocampus (Chang et al., 2003; Beaulieu et al., 2005; Emamian et al.,
2004; Zhao et al., 2006). Additionally, Par-4 and D2DR levels were positively correlated
across all samples, further evidence supporting a functional interaction between these two
factors. Calmodulin, which competes with Par-4 for D2DR binding, was unchanged across
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the diagnostic groups. Taken together, the data suggest that the Par-4/D2DR signaling
pathway is altered in major depression and, to a lesser extent, in schizophrenia, potentially
involving mechanisms of both apoptosis and dopamine signaling.
cAMP is a well established second messenger of D2DR signaling. Normally, D2DR activity
is associated with inhibition of cAMP signaling (Bonci and Hopf, 2005). However, when
Par-4 expression was knocked down by RNA interference, D2DR activation increased
cAMP activity suggesting that Par-4 is necessary for optimizing D2DR efficacy. The Par-4
mouse model of depression lacking the leucine zipper domain where Par-4 interacts with the
D2DR had increased cAMP levels (Park et al., 2005). It should be noted that the leucine
zipper domain of Par-4 could potentially interact with proteins other than D2DR (Sells et al.,
1997; Guo et al., 1998) although in a yeast two-hybrid assay the Par-4/D2DR interaction
appeared relatively specific (Park et al., 2005). These data demonstrate how the integrity of
Par-4/D2DR interactions can directly affect cAMP signaling, providing additional insight
into the mechanism by which Par-4 deficits may contribute to major depression.
Several other groups have also studied Par-4 in psychiatric illnesses. Par-4 protein levels in
lymphocytes and in postmortem frontal cortex of subjects with schizophrenia and bipolar
disorder were unchanged compared to normal matched controls (Amar et al., 2008). No
evidence for variation in the Par-4 gene was found in Japanese patients with schizophrenia,
bipolar disorder or major depression (Kishi et al., 2008). However, Chinese female patients
with schizophrenia were found to have two missense single nucleotide polymorphisms of
the Par-4 gene (Wang et al., 2008).
Transgenic mice overexpressing Par-4 have demonstrated that Par-4 inhibits the DNA-
binding activity of NF-κB (Camandola and Mattson, 2000; El-Guendy and Rangnekar,
2003), an anti-apoptotic transcription factor (Won et al., 2002). Interestingly, increased
levels of NF-κB have been found in the frontal cortex of patients with schizophrenia, bipolar
disorder, and major depression compared to normal control subjects (Sun et al., 2001). Our
findings of decreased Par-4 in subjects with major depression could potentially contribute to
evidence for a reciprocal increase in NF-κB expression. In addition, levels of anti-apoptotic
Bcl-2 protein were decreased in the temporal cortex of the same subjects with schizophrenia
that were examined in the current study (Jarskog et al., 2000). On the other hand, since Par-4
upregulation is known to suppress Bcl-2 expression (Camandola and Mattson, 2000), the
current data indicate that Par-4 likely did not account for low cortical Bcl-2 in
schizophrenia. In fact, the evidence for slightly lower Par-4 in schizophrenia is consistent
with data that apoptosis may be downregulated in schizophrenia, at least in later stages of
illness, including postmortem studies showing reduced DNA fragmentation in cingulate
cortex (Benes et al., 2003), downregulation of multiple pro-apoptotic genes in hippocampus
(Benes et al., 2006), and reduced ARTS/Sept 4 protein in frontal cortex (Gottfried et al.,
2007).
Several potentially confounding variables were considered. Because Par-4 is preferentially
localized to the postsynaptic density (Guo et al., 2001), decreased Par-4 could potentially
reflect the effects of reduced synaptic density. A number of studies have demonstrated
decreased cortical levels of synaptic marker proteins such as synaptophysin (Perrone-
Bizzozero et al., 1996; Glantz and Lewis, 1997) and SNAP-25 (Thompson et al., 1998;
Karson et al., 1999) in schizophrenia compared to controls. However, the current study
found no difference in synaptophysin levels in any of the patient groups compared to normal
controls, even when stratifying for antidepressant treatment at the time of death. The effects
of psychotropic treatment were also considered. Rats that received 2 weeks of daily
antidepressant treatment showed no effect on cortical Par-4 levels. Further, previous studies
indicate that D2DR binding is upregulated (not downregulated) in monkey prefrontal and
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temporal cortices after antipsychotic treatment (Lidow and Goldman-Rakic, 1994),
suggesting that antipsychotic treatment did not confound the evidence for lower D2DR
levels in schizophrenia. Postmortem stability of Par-4 showed a reduction of 54% in Par-4
levels over 24 hours PMI. While this is a substantial reduction, the diagnostic groups were
matched for PMI and it is unlikely that PMI exerted a differentially greater effect on Par-4 in
the major depression group compared to the other groups. D2DR levels showed no change
over 24 hours PMI. Finally, while samples were also group-matched on age, gender,
ethnicity, brain hemisphere, and brain pH, the duration of illness was significantly shorter in
the depression group compared to the schizophrenia and bipolar groups. A linear regression
analysis found no association between duration of illness and Par-4 levels (r=0.019,
p=0.898). Considered together, these potentially confounding variables do not appear to
have exerted a significant effect on the results.
In summary, this study found changes in the Par-4/D2DR receptor pathway in postmortem
temporal cortex in patients with major depression, with more subtle changes also found in
patients with schizophrenia. The pathophysiological significance of low Par-4 levels remains
uncertain; however, mechanisms involving both the regulation of apoptosis and dopamine
signaling must be considered. Given that the current findings appear to support the Par-4
mouse model of depression, further study of Par-4 in model systems and in human
postmortem brain tissue is warranted.
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Representative Western blot of Par-4 protein in temporal cortex in patients with
schizophrenia (S), bipolar disorder (B), major depression (MD) and in normal control (N)
subjects. Equal amounts of total protein were resolved on a 10% Tris-glycine
polyacrylamide gel, transferred to a PVDF membrane and incubated with a primary Par-4
antibody. Immunoreactive bands migrated to ∼45 kDa. Lane P contained a sample of pooled
cortical homogenates and lane C contained a positive control for Par-4, expressed in E. coli
as a 50 kDa polyhistidine-tagged fusion protein.
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Scatter plot of normalized optical densities (nOD) of Par-4 immunoreactive bands and
respective mean values in temporal cortex in patients with schizophrenia (Scz), bipolar
disorder (BD), major depression (MD), and in normal control (Con) subjects (n=15 per
group). Par-4 demonstrated an effect of diagnosis by ANOVA (F3,56=2.9, P<0.05). A post
hoc Tukey's multiple comparison test showed mean Par-4 level in patients with major
depression was 67% lower compared to normal controls (P<0.05).
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Representative Western blot of D2 dopamine receptor (D2DR) protein in temporal cortex in
patients with schizophrenia (S), bipolar disorder (B), major depression (MD) and in normal
control (C) subjects. Equal amounts of total protein were resolved on a 4-12% Tris-glycine
polyacrylamide gel, transferred to a PVDF membrane and incubated with a primary
antibody for D2DR. Immunoreactive bands migrating to 48 kD and 98 kD are consistent
with D2DR monomers and dimers. Lane P contained a sample of pooled cortical
homogenates.
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Scatter plots of normalized optical densities (nOD) of (A) 48 kDa immunoreactive bands
and (B) 98 kDa immunoreactive bands of D2DR and respective mean values in postmortem
temporal cortex in patients with schizophrenia (Scz, n=14), bipolar disorder (BD, n=14),
major depression (MD, n=15), and in normal control (Con, n=14) subjects. D2DR 98 kDa
demonstrated an effect of diagnosis by ANOVA (F3,53=3.3, P<0.05). A post hoc Tukey's
multiple comparison test showed mean D2DR 98 kDa levels were 55% lower in patients
with schizophrenia compared to normal controls (P<0.05).
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Scatter plot of normalized optical densities (nOD) of calmodulin-immunoreactive bands and
respective mean values in postmortem temporal cortex in patients with schizophrenia (Scz,
n=13), bipolar disorder (BD, n=13), major depression (MD, n=15), and in normal control
(Con, n=14) subjects. Calmodulin demonstrated no effect of diagnosis by ANOVA
(F3,51=0.48, P=0.70).
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Scatter plot of normalized optical densities (nOD) of synaptophysin-immunoreactive bands
and respective mean values in postmortem temporal cortex in patients with schizophrenia
(Scz, n=14), bipolar disorder (BD, n=14), major depression (MD, n=15), and in normal
control (Con, n=15) subjects. Synaptophysin demonstrated no effect of diagnosis by
ANOVA (F3,54=1.92, P=0.14).
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Brightfield photomicrograph from prefrontal cortex of Par-4 immunoreactivity in a 14 μm
thick frozen section in a 29 year old normal control subject. Scale bar = 100 μm.
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Scatter plot of integrated optical densities (IOD) of Par-4-immunoreactive bands and
respective mean values in the cortex of Flinders Sensitive Line (FSL), a rat model of
depression, and Flinders Resistant Line (FRL) rats as controls. FSL “treated” rats received
daily i.p. desmethylimipramine for 2 weeks, FSL “untreated” rats received vehicle for 2
weeks and FRL “control” rats received 2 weeks vehicle. Par-4 demonstrated no effect of
treatment between the 3 groups.
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